 Shikha Sundaram
Concepts (212)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 25 | 2025 | 842 | 4.570 |
Why?
| | Biliary Atresia | 9 | 2024 | 154 | 2.850 |
Why?
| | Sarcopenia | 4 | 2023 | 81 | 2.240 |
Why?
| | Non-alcoholic Fatty Liver Disease | 10 | 2024 | 279 | 2.100 |
Why?
| | Cholestasis | 4 | 2025 | 209 | 1.180 |
Why?
| | End Stage Liver Disease | 2 | 2021 | 81 | 1.110 |
Why?
| | Liver Diseases | 2 | 2025 | 301 | 0.990 |
Why?
| | Human Growth Hormone | 1 | 2025 | 48 | 0.920 |
Why?
| | Muscular Atrophy | 1 | 2025 | 87 | 0.900 |
Why?
| | Sleep Apnea, Obstructive | 2 | 2018 | 303 | 0.720 |
Why?
| | Child | 35 | 2025 | 21990 | 0.720 |
Why?
| | Hepatoblastoma | 1 | 2022 | 45 | 0.710 |
Why?
| | Hepatopulmonary Syndrome | 2 | 2021 | 25 | 0.690 |
Why?
| | Hypoxia | 3 | 2018 | 1121 | 0.670 |
Why?
| | Malnutrition | 1 | 2021 | 85 | 0.670 |
Why?
| | Fatty Liver | 3 | 2013 | 242 | 0.630 |
Why?
| | Carcinoma, Hepatocellular | 2 | 2022 | 359 | 0.590 |
Why?
| | Liver Failure, Acute | 2 | 2024 | 65 | 0.540 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2018 | 92 | 0.530 |
Why?
| | Hypertension, Portal | 1 | 2017 | 66 | 0.500 |
Why?
| | Liver Neoplasms | 2 | 2022 | 759 | 0.490 |
Why?
| | Severity of Illness Index | 7 | 2022 | 2838 | 0.480 |
Why?
| | Muscle, Skeletal | 1 | 2025 | 1747 | 0.470 |
Why?
| | Preoperative Care | 1 | 2017 | 354 | 0.430 |
Why?
| | Waiting Lists | 4 | 2021 | 258 | 0.430 |
Why?
| | Liver | 7 | 2022 | 1874 | 0.420 |
Why?
| | Oxidative Stress | 2 | 2018 | 1322 | 0.400 |
Why?
| | Graft Survival | 6 | 2022 | 526 | 0.400 |
Why?
| | Postoperative Complications | 4 | 2025 | 2671 | 0.380 |
Why?
| | Infant | 13 | 2025 | 9566 | 0.380 |
Why?
| | Obesity | 4 | 2022 | 3037 | 0.380 |
Why?
| | Humans | 45 | 2025 | 138102 | 0.360 |
Why?
| | Adolescent | 15 | 2025 | 21637 | 0.350 |
Why?
| | Metabolic Syndrome | 2 | 2013 | 354 | 0.320 |
Why?
| | Metabolism, Inborn Errors | 1 | 2008 | 39 | 0.290 |
Why?
| | Fructose | 2 | 2022 | 112 | 0.280 |
Why?
| | Biomarkers | 5 | 2024 | 4111 | 0.280 |
Why?
| | Infant Mortality | 1 | 2008 | 114 | 0.270 |
Why?
| | F2-Isoprostanes | 2 | 2018 | 21 | 0.270 |
Why?
| | Eosinophilic Esophagitis | 2 | 2025 | 325 | 0.270 |
Why?
| | Quality of Life | 3 | 2023 | 2936 | 0.270 |
Why?
| | Portoenterostomy, Hepatic | 3 | 2022 | 42 | 0.270 |
Why?
| | Child, Preschool | 14 | 2025 | 11142 | 0.260 |
Why?
| | Retrospective Studies | 15 | 2025 | 15750 | 0.260 |
Why?
| | Bile Acids and Salts | 1 | 2008 | 154 | 0.260 |
Why?
| | Living Donors | 4 | 2022 | 292 | 0.260 |
Why?
| | Chronic Disease | 2 | 2025 | 1791 | 0.240 |
Why?
| | Alagille Syndrome | 2 | 2024 | 28 | 0.240 |
Why?
| | Cholestasis, Intrahepatic | 2 | 2023 | 30 | 0.240 |
Why?
| | Absorptiometry, Photon | 1 | 2025 | 265 | 0.220 |
Why?
| | alpha-Fetoproteins | 1 | 2024 | 40 | 0.220 |
Why?
| | Female | 21 | 2025 | 73648 | 0.210 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2024 | 40 | 0.210 |
Why?
| | Male | 21 | 2025 | 67984 | 0.210 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2025 | 328 | 0.200 |
Why?
| | Cross-Sectional Studies | 4 | 2025 | 5556 | 0.200 |
Why?
| | Bone Diseases, Metabolic | 1 | 2023 | 63 | 0.200 |
Why?
| | Survival Rate | 4 | 2017 | 1912 | 0.190 |
Why?
| | Elasticity Imaging Techniques | 1 | 2022 | 59 | 0.180 |
Why?
| | Health Services Accessibility | 2 | 2021 | 996 | 0.180 |
Why?
| | Hepatic Veins | 1 | 2021 | 33 | 0.180 |
Why?
| | Airway Extubation | 1 | 2022 | 59 | 0.180 |
Why?
| | Dietary Carbohydrates | 1 | 2022 | 155 | 0.180 |
Why?
| | Abdominal Fat | 1 | 2021 | 41 | 0.180 |
Why?
| | Immunosuppressive Agents | 2 | 2017 | 863 | 0.170 |
Why?
| | Endoscopy, Digestive System | 2 | 2025 | 135 | 0.170 |
Why?
| | Vaccination | 2 | 2020 | 1431 | 0.170 |
Why?
| | Vascular Malformations | 1 | 2021 | 52 | 0.170 |
Why?
| | Infant, Newborn | 7 | 2024 | 6140 | 0.170 |
Why?
| | Nutritional Status | 2 | 2021 | 354 | 0.170 |
Why?
| | Treatment Outcome | 7 | 2022 | 10832 | 0.170 |
Why?
| | Metabolic Diseases | 1 | 2021 | 108 | 0.170 |
Why?
| | Portal Vein | 1 | 2021 | 118 | 0.170 |
Why?
| | Cohort Studies | 5 | 2022 | 5731 | 0.160 |
Why?
| | Primary Graft Dysfunction | 1 | 2020 | 32 | 0.160 |
Why?
| | gamma-Glutamyltransferase | 2 | 2011 | 42 | 0.160 |
Why?
| | Vaccines, Attenuated | 1 | 2020 | 131 | 0.160 |
Why?
| | Remission Induction | 1 | 2020 | 291 | 0.160 |
Why?
| | Body Mass Index | 3 | 2022 | 2422 | 0.160 |
Why?
| | Enteral Nutrition | 1 | 2021 | 200 | 0.160 |
Why?
| | Eating | 1 | 2022 | 397 | 0.160 |
Why?
| | Postoperative Care | 1 | 2020 | 265 | 0.150 |
Why?
| | Transplant Recipients | 1 | 2020 | 186 | 0.140 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2021 | 309 | 0.140 |
Why?
| | Case-Control Studies | 1 | 2025 | 3569 | 0.140 |
Why?
| | Practice Patterns, Physicians' | 2 | 2017 | 1299 | 0.140 |
Why?
| | Thioguanine | 1 | 2017 | 19 | 0.140 |
Why?
| | Hepatitis, Autoimmune | 1 | 2017 | 18 | 0.140 |
Why?
| | Aspartate Aminotransferases | 2 | 2022 | 84 | 0.130 |
Why?
| | Azathioprine | 1 | 2017 | 49 | 0.130 |
Why?
| | Emotional Adjustment | 1 | 2017 | 18 | 0.130 |
Why?
| | Anesthetics, Intravenous | 1 | 2017 | 48 | 0.130 |
Why?
| | Glucose | 1 | 2022 | 1033 | 0.130 |
Why?
| | Pediatrics | 2 | 2016 | 1074 | 0.130 |
Why?
| | Adiposity | 1 | 2021 | 527 | 0.130 |
Why?
| | Propofol | 1 | 2017 | 74 | 0.130 |
Why?
| | Tissue and Organ Procurement | 1 | 2020 | 318 | 0.120 |
Why?
| | Family Relations | 1 | 2017 | 91 | 0.120 |
Why?
| | Societies, Medical | 1 | 2020 | 820 | 0.120 |
Why?
| | Aldehydes | 1 | 2016 | 144 | 0.120 |
Why?
| | Nicardipine | 1 | 2015 | 5 | 0.120 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2022 | 1052 | 0.120 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2017 | 125 | 0.120 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2022 | 611 | 0.120 |
Why?
| | Prevalence | 3 | 2025 | 2762 | 0.120 |
Why?
| | Insulin Resistance | 2 | 2021 | 1231 | 0.110 |
Why?
| | Healthcare Disparities | 1 | 2021 | 662 | 0.110 |
Why?
| | Communicable Diseases | 1 | 2017 | 161 | 0.110 |
Why?
| | Pediatric Obesity | 1 | 2021 | 612 | 0.110 |
Why?
| | Food Hypersensitivity | 1 | 2017 | 182 | 0.110 |
Why?
| | Immunization | 1 | 2016 | 405 | 0.110 |
Why?
| | Gastroenterology | 1 | 2016 | 178 | 0.110 |
Why?
| | Tacrolimus | 1 | 2015 | 195 | 0.100 |
Why?
| | Hyperuricemia | 1 | 2013 | 44 | 0.100 |
Why?
| | Multivariate Analysis | 2 | 2017 | 1495 | 0.100 |
Why?
| | Dietary Sucrose | 1 | 2013 | 49 | 0.100 |
Why?
| | Health Policy | 1 | 2017 | 397 | 0.100 |
Why?
| | Sweetening Agents | 1 | 2013 | 55 | 0.100 |
Why?
| | Follow-Up Studies | 4 | 2021 | 5144 | 0.100 |
Why?
| | Registries | 3 | 2022 | 2059 | 0.100 |
Why?
| | Pilot Projects | 1 | 2018 | 1751 | 0.100 |
Why?
| | Uric Acid | 1 | 2013 | 165 | 0.090 |
Why?
| | Confidence Intervals | 1 | 2012 | 334 | 0.090 |
Why?
| | Steroids | 1 | 2012 | 159 | 0.090 |
Why?
| | Hemochromatosis | 1 | 2011 | 10 | 0.090 |
Why?
| | Hyperbilirubinemia | 1 | 2011 | 12 | 0.090 |
Why?
| | Hepatic Encephalopathy | 1 | 2011 | 21 | 0.090 |
Why?
| | International Normalized Ratio | 1 | 2011 | 46 | 0.090 |
Why?
| | Inflammation | 1 | 2022 | 2847 | 0.090 |
Why?
| | Nutrition Surveys | 1 | 2012 | 270 | 0.090 |
Why?
| | Parenteral Nutrition | 1 | 2012 | 104 | 0.080 |
Why?
| | Regression Analysis | 1 | 2013 | 1012 | 0.080 |
Why?
| | Alanine Transaminase | 1 | 2011 | 150 | 0.080 |
Why?
| | Reoperation | 2 | 2015 | 579 | 0.080 |
Why?
| | Herpes Simplex | 1 | 2011 | 94 | 0.080 |
Why?
| | Length of Stay | 2 | 2022 | 1214 | 0.080 |
Why?
| | Odds Ratio | 1 | 2012 | 1077 | 0.080 |
Why?
| | Models, Statistical | 1 | 2013 | 665 | 0.080 |
Why?
| | Prognosis | 3 | 2024 | 3982 | 0.070 |
Why?
| | Pruritus | 1 | 2008 | 61 | 0.070 |
Why?
| | Body Composition | 2 | 2022 | 695 | 0.070 |
Why?
| | Overweight | 1 | 2012 | 577 | 0.070 |
Why?
| | Dietary Supplements | 1 | 2012 | 565 | 0.070 |
Why?
| | Antibiotic Prophylaxis | 1 | 2008 | 119 | 0.070 |
Why?
| | Logistic Models | 1 | 2012 | 2081 | 0.070 |
Why?
| | Hospitalization | 1 | 2017 | 2195 | 0.060 |
Why?
| | Energy Intake | 2 | 2023 | 506 | 0.060 |
Why?
| | Time Factors | 1 | 2017 | 6845 | 0.060 |
Why?
| | Pregnancy | 3 | 2023 | 6789 | 0.060 |
Why?
| | Predictive Value of Tests | 2 | 2024 | 2029 | 0.060 |
Why?
| | United States | 5 | 2021 | 15028 | 0.060 |
Why?
| | Prospective Studies | 2 | 2021 | 7603 | 0.060 |
Why?
| | Comorbidity | 1 | 2009 | 1638 | 0.050 |
Why?
| | Mitochondrial Diseases | 1 | 2024 | 91 | 0.050 |
Why?
| | Sugars | 1 | 2023 | 41 | 0.050 |
Why?
| | Risk Factors | 2 | 2017 | 10433 | 0.050 |
Why?
| | Plethysmography | 1 | 2022 | 108 | 0.050 |
Why?
| | ROC Curve | 1 | 2024 | 563 | 0.050 |
Why?
| | Graft Rejection | 2 | 2017 | 577 | 0.050 |
Why?
| | Aged | 1 | 2022 | 23995 | 0.050 |
Why?
| | Anthropometry | 1 | 2022 | 215 | 0.050 |
Why?
| | Vaccines | 2 | 2017 | 402 | 0.040 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2022 | 158 | 0.040 |
Why?
| | Maternal Nutritional Physiological Phenomena | 1 | 2023 | 177 | 0.040 |
Why?
| | Constriction, Pathologic | 1 | 2022 | 238 | 0.040 |
Why?
| | North America | 1 | 2022 | 309 | 0.040 |
Why?
| | Age Factors | 1 | 2008 | 3285 | 0.040 |
Why?
| | Risk Assessment | 2 | 2022 | 3471 | 0.040 |
Why?
| | Liver Cirrhosis | 1 | 2022 | 312 | 0.040 |
Why?
| | Incidence | 2 | 2017 | 2827 | 0.040 |
Why?
| | Cholesterol, LDL | 1 | 2022 | 373 | 0.040 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 2022 | 210 | 0.040 |
Why?
| | Triglycerides | 1 | 2022 | 528 | 0.040 |
Why?
| | Birth Weight | 1 | 2022 | 511 | 0.040 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2013 | 2562 | 0.040 |
Why?
| | Fatigue | 1 | 2021 | 338 | 0.040 |
Why?
| | Respiration, Artificial | 1 | 2022 | 639 | 0.030 |
Why?
| | Maintenance Chemotherapy | 1 | 2017 | 36 | 0.030 |
Why?
| | Contraindications, Drug | 1 | 2017 | 8 | 0.030 |
Why?
| | Transplantation Immunology | 1 | 2017 | 32 | 0.030 |
Why?
| | Induction Chemotherapy | 1 | 2017 | 78 | 0.030 |
Why?
| | Diet Therapy | 1 | 2017 | 38 | 0.030 |
Why?
| | Palivizumab | 1 | 2016 | 12 | 0.030 |
Why?
| | Young Adult | 1 | 2013 | 13329 | 0.030 |
Why?
| | Gastrointestinal Agents | 1 | 2017 | 64 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2017 | 424 | 0.030 |
Why?
| | Liver Failure | 1 | 2016 | 86 | 0.030 |
Why?
| | Immunocompromised Host | 1 | 2017 | 204 | 0.030 |
Why?
| | Canada | 1 | 2016 | 409 | 0.030 |
Why?
| | Diet | 1 | 2023 | 1290 | 0.030 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2015 | 156 | 0.030 |
Why?
| | Immunization Programs | 1 | 2016 | 217 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2021 | 2861 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1234 | 0.030 |
Why?
| | Drug Interactions | 1 | 2015 | 406 | 0.030 |
Why?
| | Drug Monitoring | 1 | 2015 | 209 | 0.030 |
Why?
| | Bariatric Surgery | 1 | 2017 | 218 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2015 | 753 | 0.020 |
Why?
| | Exercise Therapy | 1 | 2017 | 441 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2016 | 743 | 0.020 |
Why?
| | Skinfold Thickness | 1 | 2012 | 46 | 0.020 |
Why?
| | Animals | 2 | 2013 | 37151 | 0.020 |
Why?
| | Antihypertensive Agents | 1 | 2015 | 499 | 0.020 |
Why?
| | Adult | 1 | 2013 | 38063 | 0.020 |
Why?
| | Weight Gain | 1 | 2013 | 538 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1557 | 0.020 |
Why?
| | Feeding Behavior | 1 | 2013 | 685 | 0.020 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2013 | 618 | 0.020 |
Why?
| | Colorado | 1 | 2017 | 4553 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2016 | 5850 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2013 | 4309 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2013 | 2121 | 0.010 |
Why?
|
|
Sundaram's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|